Department Metrics

• Impact of extracellular glutathione catabolism on triple-negative breast cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:DeNicola, G.
• Translational studies for targeted alpha-particle therapy for rare melanomas
  Award Number:
  Sponsor: US Army
  PI:Morse, D.
• Improving therapy for leptomeningeal Non-Hodgkin B cell lymphoma by targeting the metabolic tumor microenvironment
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Smalley, I.

CLINICAL TRIAL 50521
Integrated Plasma Metabolomic and Cytokine Profiling to Characterize Cancer Cachexia
Condition: Thoracic
Intervention:

• Noble JD, Peixoto BC, Menges MA, Abraham-Miranda J, Savid-Frontera C, Sawyer W, Sorathia VD, Cuadrado Delgado LA, Corallo SA, Llanos JC, Merritt EC, De Avila G, Castaneda-Puglianini OA, Liu HD, Alsina M, Nishihori T, Shain KH, Siqueira Silva AS, Baz RC, Blue BJ, Grajales-Cruz AF, Hansen DK, Cleveland JL, Perna F, Lynch CC, Binning JM, Atkins RM, Song X, Locke FL, Freeman CL. Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. Blood. 2026 Sep.148(11):1409-1422. Pubmedid: 42275255.
• Sun LJ, DeNicola GM. A mitochondrial antioxidant axis fuels iron addiction in colorectal cancer. Cell Metab. 2026 Aug.38(8):1521-1523. Pubmedid: 42551410.
• Buro AW, Gomez MF, Kim Y, Ward NP, Umbarger M, Ma L, Vala A, Hogue S, Silva WV, Bailey A, Pierce CM, Kim Y, DeNicola GM, Byrd DA, Robinson LA. Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung Cancer. Res Sq. 2026 Jul. Pubmedid: 42466390. Pmcid: PMC13370620.
• Persi E, Canevarolo R, Sudalagunta PR, Xu L, Karbalaei K, Olgun G, Wolf Y, Hannenhalli S, Koonin E, Silva AS. Fluctuating environment causes neoplastic transition and epithelial-mesenchymal plasticity in human cells. Res Sq. 2026 Jul. Pubmedid: 42620177. Pmcid: PMC13484392.
• Ataya DK, Fernando KRM, Brainerd J, De La Cruz Y, Abdalah M, Stringfield O, Sobhani E, Raghunand N, Bui M, El Naqa I, Niell BL. Ductal Carcinoma In Situ Active Monitoring Trials: Do Eligibility Criteria Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?. J Breast Imaging. 2026 Jul.8(4):387-394. Pubmedid: 41774047. Pmcid: PMC13408781.
• Kim HH, Zhang EY, Palma FR, Kant A, Martinez-Sarmiento JA, Guo Z, Mauck RL, Shenoy V, Bonini MG, Heo SC, Lakadamyali M. O-SNAP uncovers nanoscale chromatin remodeling in dedifferentiation and stress responses. Nat Commun. 2026 Jun.17(1). Pubmedid: 42236704. Pmcid: PMC13396410.
• Canevarolo RR, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, DeAvila D, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst L, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer J, Dalton W, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple Myeloma. Cancer Res. 2026 Jun. Pubmedid: 42233980.
• Churchman M, Lu X, McKean D, Radmacher M, Zhang Q, Rounbehler R, Tan A, Shaw T, Obermayer A, Grass G, Spakowicz D, Tarhini A, Shain K, Canevarolo R, Meads M, Silva AS, Sudalagunta PR, Manley B, Huntsman S, Collyar D, Kolesar J, Evers BM, Single N, Edge S, Johnson C, Weiner G, McCarter M, Borges V, Horne L, Lillard J, Mudaranthakam D, White J, Libutti S, Ganesan S, Riedlinger G, Loughran T, Halme D, Johns M, Arciero C, Salhia B, Naqash AR, Shriver C, Lee K, Schneider B, Nix D, Fillmore G, Colman H, Ulrich C, Springer B, Pollock R, Vucic E, Sherman J, Jain A, Dalton W, Agius P, Siegel E. The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology. Res Sq. 2026 Jun. Pubmedid: 42281974. Pmcid: PMC13252564.
• Schmidt EE, Jurányi EP, Miller CG, Austad SA, Ditrói T, Seaford ZM, Yoon SJ, Noyd RC, Kang YP, Prigge JR, Csikós V, Serrano Alvarez M, Erdélyi K, Kővári D, DeNicola GM, Nagy P. Cystine C-S bond cleavage fuels cysteine production under disulfide reductase deficiency. Nat Chem Biol. 2026 May. Pubmedid: 42168626.
• Welles JE, Garifallou JP, Gonzalez MV, Santoleri D, Choudhury FK, DeNicola GM, Martin RW, Jiang C, Kim J, Li G, Aki Y, Chang CJ, Li D, Wells RG, Xiao Y, Zhang J, Lazar MA, Brady DC, Titchenell PM. Reduction in Hepatic Phosphatidylcholine Biosynthesis Promotes MASH Through Copper Deficiency. bioRxiv. 2026 May. Pubmedid: 42182421. Pmcid: PMC13192769.
• Piña Y, Umeh Garcia M, Boire A, Brenner A, Camidge DR, Chang S, Forsyth PA, Hayden Gephart M, Olayinka Kamson D, Kumthekar P, Quant Lee E, Le Rhun E, O'Brien B, Pentsova E, Piccioni D, Remsik J, Smalley I, Wefel J, Weller M, Wilcox J, Yang JT, Nagpal S, Glitza Oliva IC. Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration. Neurooncol. 2026 May. Pubmedid: 42202212.
• Ghosh S, Jarvis AF, Hintzen JCJ, McKnight NR, Costa-Pinheiro P, Noughton NH, Kim Y, Jaccard A, Leary SC, Cobine PA, Bartman CR, DeNicola GM, Snyder NW, Wellen KE, Burslem GM, Brady DC. Mitochondrial copper stabilizes lipoylated TCA cycle proteins to sustain metabolism and proliferation. bioRxiv. 2026 May. Pubmedid: 42239150. Pmcid: PMC13228588.
• Hecht F, Zocchi M, Tuttle ET, Ward NP, Alimohammadi F, Khan AA, Gomes VC, Smith B, Twardowski JJ, Mills BN, Welle KA, Ghaemmaghami S, Zhou Z, Gan Y, Kang YP, Cazarin J, Soares ZG, Ozgurses ME, Zhao H, Sheehan C, Cognet G, Munger LD, Trivedi D, Asantewaa G, Blick-Nitko SK, Zoeller JJ, Chen Y, Vasiliou V, Turner BM, Mello SS, Altman BJ, Muir A, Coloff JL, Munger J, DeNicola GM, Harris IS. Catabolism of extracellular glutathione supplies cysteine to support tumours. Nature. 2026 May.653(8115):933-941. Pubmedid: 41851454. Pmcid: PMC13190318.
• Patra P, Jacome M, Ahmed KA, Yang JT, Smalley I, Forsyth PA, Piña Y. A New Era in Leptomeningeal Disease (LMD): Recent Advancements in Immunocellular and Radiation Therapies in Melanoma LMD, What Has Been Done and Future Directions. Pigment Cell Melanoma Res. 2026 May.39(3):e70082. Pubmedid: 42003166.
• Fang Y, Kim J, Thompson ZJ, Kim Y, Ravi H, Mazin A, Moran Segura CM, Nguyen JV, Macaulay RJ, Veglia F, Thompson RC, Chowdhary SA, Egan KM, Raghunand N. Immune Subtypes and Survival in Patients with Primary Glioma. medRxiv. 2026 Apr. Pubmedid: 42094160. Pmcid: PMC13142596.
• Brain JA, Vigil ABG, Davidsen K, Itokawa A, Jurasin AC, Kerbyson HJ, Kobiesa M, Hart ML, Yoon SJ, Bellotti P, Maianti JP, DeNicola GM, Sullivan LB. Excess cysteine drives conjugate formation and impairs proliferation of NRF2-activated cancer cells. Nat Metab. 2026 Apr.8(4):840-854. Pubmedid: 41946999. Pmcid: PMC13121033.
• Tiek D, Song X, Wu R, Yu X, Walker M, Mao Y, Sisbarro D, He Q, Magassa A, Singh A, Lu J, Sharma AK, Miska J, Hu B, Bonini MG, Zhang X, Cheng SY. Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds. Neurooncol. 2026 Mar.28(3):613-625. Pubmedid: 41212520. Pmcid: PMC13070503.
• Vallebuona EJ, Smalley I. Spatially Resolved Opto-Omics Uncovers Functional Microglial Subtypes in Brain Metastasis. Cancer Res. 2026 Mar.86(6):1345-1346. Pubmedid: 41834497.
• Kim Y, Sun LJ, Long M, Caldwell S, Maurer HC, Olive KP, Karreth F, DeNicola GM. PHGDH is a targetable driver of PDAC progression. bioRxiv. 2026 Mar. Pubmedid: 41959234. Pmcid: PMC13060845.
• Choudhury FK, DeNicola GM. Best practices for cysteine analysis. Ferroptosis Oxid Stress. 2026 Feb.2. Pubmedid: 41736907. Pmcid: PMC12928759.
• Dhahri H, Lau KH, Saintilnord WN, Lopes E, Damico HN, Hegazy YA, Palma FR, Melters DP, Chandler DP, Dalal Y, Licht JD, Bonini MG, Fondufe-Mittendorf YN. Single amino-acid differences define H2B variants and modify chromatin accessibility to induce EMT in breast cancer. Oncogene. 2026 Feb.45(6):669-689. Pubmedid: 41580505. Pmcid: PMC12867764.
• Bryant JM, Shotbolt M, Stimphil E, Andre V, Zhang E, Estrella V, Husain K, Weygand J, Marchion D, Lopez AS, Abrahams D, Chen S, Abdel-Mottaleb M, Conlan S, Oraiqat I, Khatri V, Guevara JA, Pilon-Thomas S, Redler G, Latifi K, Raghunand N, Yamoah K, Hoffe S, Costello J, Frakes JM, Liang P, Gatenby RA, Malafa M, Khizroev S. Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models. Adv Sci (Weinh). 2026 Feb.13(9):e17228. Pubmedid: 41178530. Pmcid: PMC12904064.
• Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, Garces JJ, Firestone R, Braggio E, Asmann Y, Durante M, Diamond BT, Papadimitriou M, Hultcrantz M, Marella A, Castellano G, Maeda A, Lionetti M, Matera A, Pioggia S, Da Vià MC, de Magistris C, Leongamornlert D, DeAvila D, Sudalagunta PR, Canevarolo RR, Siegel EM, Agius P, Teer J, McPherson A, Yamashita Y, Silva AS, Blaney P, Baz R, Patel KK, Campbell P, Morgan G, Fonseca R, Landgren O, Orlowski RZ, Shain KH, Bolli N, Usmani S, Rajkumar SV. Genomics Define Malignant Transformation in Myeloma Precursor Conditions. J Clin Oncol. 2026 Jan.44(3):188-199. Pubmedid: 41061199. Pmcid: PMC12614327.
• Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2026 Jan.147(5):497-512. Pubmedid: 40983035.
• Hammami MB, Canevarolo RR, Silva AS, Alsina M, Kumar N, Baz R, Shain KH. Navigating the evolving management of smoldering multiple myeloma. Hemasphere. 2026 Jan.10(1):e70275. Pubmedid: 41523082. Pmcid: PMC12784114.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Dec.43(12):2298-2310.e6. Pubmedid: 41072416. Pmcid: PMC12614569.
• Kim Y, Caldwell S, Long M, Abrahams D, Baldwin M, DeNicola GM. A simple, anesthesia-free infusion technique for in vivo metabolic tracing. bioRxiv. 2025 Dec. Pubmedid: 41473331. Pmcid: PMC12746135.
• Yasseen BA, DeNicola GM. Can't KEEP Up: UXS1 Dependency Exposes a Pyrimidine Vulnerability in KEAP1-Mutant Lung Cancer. Cancer Res. 2025 Dec.85(23):4582-4584. Pubmedid: 41321105.
• Maura F, Freeman CL, Maclachlan KH, Ilundain ML, Ziccheddu B, Meermeier EW, Garces JJ, Durante M, Lee H, Firestone R, Menges M, Reid K, Diamond B, Papadimitriou M, Silva AS, Sudalagunta PR, Leblay N, Ahn S, Fuller E, Briercheck E, Sharik ME, Du MT, Agius P, Hansen DK, Song X, Zhao X, Meads MB, Teer J, Jelinek T, Hagner P, Baz R, Alsina M, Ramasubramanian AM, Smith E, Giralt SA, Mailankody S, Bergsagel LP, Neri P, Chesi M, Martinez-Climent JA, Locke FL, Bahlis NJ, Landgren O, Hamadeh I, Usmani SZ, Shain KH. Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma. bioRxiv. 2025 Dec. Pubmedid: 41415462. Pmcid: PMC12710967.
• Weinfurtner RJ, Ataya D, Funaro K, Bhatt A, Abdalah M, Stringfield O, Raghunand N, Thompson Z, Lee MC, Czerniecki B, Muller AS, Soliman H, Han H. Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy. Clin Imaging. 2025 Nov.127:110618. Pubmedid: 40945432.